Kwality Pharmaceuticals Ltd

Kwality Pharmaceuticals Ltd

₹ 533 5.00%
24 May - close price
About

Incorporated in 1983, Kwality Pharma is in the business of manufacturing & trading in Pharmaceuticals & allied products[1]

Key Points

Business Overview:[1][2]
KPL is in an ANVISA and EU GMP certified manufacturer of all pharma products including complex molecules across all dosage forms including niche Biologics. It has a portfolio of 3000+ formulations across 25+ therapeutic areas with categories including generics, cephalosporin, beta-lactam, oncology & biologics. It manufactures and deals in drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations

  • Market Cap 553 Cr.
  • Current Price 533
  • High / Low 545 / 250
  • Stock P/E 18.9
  • Book Value 218
  • Dividend Yield 0.00 %
  • ROCE 15.9 %
  • ROE 13.7 %
  • Face Value 10.0

Pros

  • Company has delivered good profit growth of 31.2% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 34.2%

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Debtor days have increased from 100 to 138 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
120.19 183.71 88.19 64.04 70.22 55.96 56.01 68.80 67.45 69.65 78.10 91.98
72.66 100.29 63.65 47.81 52.20 40.39 40.84 57.28 53.64 54.38 61.40 71.11
Operating Profit 47.53 83.42 24.54 16.23 18.02 15.57 15.17 11.52 13.81 15.27 16.70 20.87
OPM % 39.55% 45.41% 27.83% 25.34% 25.66% 27.82% 27.08% 16.74% 20.47% 21.92% 21.38% 22.69%
0.96 0.12 0.84 1.60 0.38 0.75 0.35 -15.07 0.40 0.23 0.62 -6.52
Interest 0.68 0.71 0.50 1.03 1.22 1.18 1.95 1.67 2.19 2.41 2.73 3.06
Depreciation 2.06 2.65 3.19 2.75 3.13 3.83 3.54 4.42 4.78 4.88 4.81 5.04
Profit before tax 45.75 80.18 21.69 14.05 14.05 11.31 10.03 -9.64 7.24 8.21 9.78 6.25
Tax % 24.92% 25.59% 26.74% 25.27% 24.91% 20.07% 27.92% 23.65% 24.72% 23.75% 21.17% 28.00%
34.35 59.66 15.89 10.51 10.55 9.05 7.23 -7.36 5.45 6.26 7.70 4.50
EPS in Rs 33.10 57.50 15.31 10.13 10.17 8.72 6.97 -7.09 5.25 6.03 7.42 4.34
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
62 60 52 76 95 137 165 138 261 456 251 307
58 56 49 70 86 125 149 124 231 284 190 241
Operating Profit 3 4 4 6 9 12 15 14 29 172 61 67
OPM % 5% 6% 7% 8% 9% 8% 9% 10% 11% 38% 24% 22%
0 0 1 0 2 1 1 4 2 4 -14 -5
Interest 1 1 1 1 2 2 2 3 3 3 7 10
Depreciation 1 1 1 2 2 3 3 4 6 11 15 20
Profit before tax 2 2 2 3 6 8 11 11 22 162 26 31
Tax % 27% 47% 29% 39% 41% 38% 31% 24% 29% 26% 24% 24%
1 1 1 2 3 5 8 8 15 120 19 24
EPS in Rs 1.66 0.95 1.32 1.89 3.31 4.51 7.28 8.12 14.86 115.70 18.76 23.11
Dividend Payout % 0% 0% 0% 0% 9% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 18%
5 Years: 13%
3 Years: 6%
TTM: 22%
Compounded Profit Growth
10 Years: 41%
5 Years: 31%
3 Years: 24%
TTM: -8%
Stock Price CAGR
10 Years: %
5 Years: 69%
3 Years: 72%
1 Year: 105%
Return on Equity
10 Years: 30%
5 Years: 33%
3 Years: 34%
Last Year: 14%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 4 4 4 5 5 10 10 10 10 10 10 10
Reserves 8 13 15 18 21 21 28 37 52 172 192 216
6 6 8 13 19 26 28 35 41 54 90 98
11 12 10 17 27 41 40 53 65 106 71 74
Total Liabilities 29 35 38 52 72 98 107 135 169 343 364 398
10 11 11 11 16 19 28 42 56 91 120 138
CWIP 0 0 0 0 0 0 0 0 3 12 14 0
Investments 1 3 4 5 7 9 8 8 9 4 4 4
18 21 23 36 50 70 71 86 102 236 226 256
Total Assets 29 35 38 52 72 98 107 135 169 343 364 398

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
8 -0 1 -3 4 -0 12 6 26 59 42 43
-1 -4 -1 -2 -7 -6 -11 -17 -23 -63 -48 -26
-5 3 1 5 5 5 -2 12 1 6 1 -17
Net Cash Flow 2 -2 0 0 1 -1 -1 1 4 2 -5 -0

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 42 41 63 95 87 99 86 80 53 57 107 138
Inventory Days 33 58 61 54 72 54 34 94 38 97 310 187
Days Payable 31 58 40 61 67 79 52 96 58 63 117 106
Cash Conversion Cycle 44 41 85 89 92 74 68 78 33 91 300 219
Working Capital Days 35 60 81 87 79 76 62 99 48 89 212 196
ROCE % 14% 12% 11% 15% 19% 19% 21% 18% 26% 97% 18%

Shareholding Pattern

Numbers in percentages

Mar 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
54.13% 54.24% 54.24% 54.43% 54.45% 54.44% 54.44% 54.73% 54.73% 54.76% 54.76% 54.82%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.00%
45.87% 45.76% 45.76% 45.57% 45.55% 45.56% 45.54% 45.25% 45.25% 45.22% 45.22% 45.17%
No. of Shareholders 1481683795811,0494,1985,3766,2116,9436,2915,7865,695

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents